Business
Is Moderna stock a hold?
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
A recent downgrade from buy to hold from a Wall Street analyst has Moderna (NASDAQ: MRNA) stock under pressure. Needham analyst Alan Carr has removed his $110 price target on the stock, citing valuation concerns.
Moderna’s market cap has swelled 885% this year to around $67 billion at recent prices. Despite coming under pressure recently, this is still one of the best performing large-cap healthcare stocks of 2020.
Following a meeting on 17 December with the Food and Drug Administration’s independent advisory committee, Moderna’s coronavirus vaccine candidate MRNA-1273 will probably become the second vaccine to earn an…
-
General14 hours agoAbattoir worker in serious condition after workplace accident in Echuca
-
General19 hours ago‘Sovereign citizens’ sentenced to prison term in Western Australia for defiance of court order
-
Noosa News21 hours agoBroncos media boss Melissa Mallet to face court over alleged drink-driving crash
-
General14 hours agoWoman who reported NSW MP Gareth Ward’s alleged sex crimes cross-examined